ABSTRACT Essential oil extracted from eucalyptus leaves has a long folkloric history of being used for the treatment of respiratory conditions. The primary terpenoid constituent in the essential oil of eucalyptus (EOE) is eucalyptol (1,8-cineole or cineole), which has been studied in both preclinical and clinical settings. Eucalyptol displays several pharmacologic activities that may provide therapeutic effects in respiratory conditions such as anti-inflammatory and bronchodilatory effects. Several clinical trials have been performed in persons affected with respiratory illness such as rhinosinusitis, bronchitis, asthma and chronic obstructive pulmonary disorder (COPD) with positive results. The objectives of this review are to provide a mechanistic overview of EOE with a focus on the primary constituent eucalyptol, summarize the pharmacology of eucalyptol in respiratory conditions, describe clinical trial data that has been generated by studying eucalyptol in humans for respiratory conditions, and discuss clinical and safety considerations for the use of EOE or eucalyptol.

中文翻译：

---

桉油精（1,8-桉树脑）：呼吸系统疾病中未被充分利用的盟友？

摘要 从桉树叶中提取的精油在用于治疗呼吸系统疾病方面有着悠久的民间历史。桉树精油 (EOE) 中的主要萜类成分是桉油精（1,8-桉树脑或桉树脑），已在临床前和临床环境中进行了研究。桉叶油素具有多种药理活性，可在呼吸系统疾病中发挥治疗作用，例如抗炎和支气管扩张作用。已经在患有鼻窦炎、支气管炎、哮喘和慢性阻塞性肺疾病 (COPD) 等呼吸道疾病的人群中进行了多项临床试验，并取得了积极的结果。本综述的目的是提供 EOE 的机械概述，重点是主要成分桉树油，